Disperazol prevents formation of, and dismantles already established biofilm infections.
c-di-GMP is not produced by humans suggesting that c-di-GMP signalling is a promising, biofilm-specific drug target with reduced risk of side effects.
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
- OTHER / NA
Infectious disease area:
- North America
- South America
Expertise in, and infrastructure for, clinical development as well as access to finance. A strategic partner that will open pathways for engagement with PE Investors or VC’s to overcome the financial hurdles of executing Ph I trials.
Spin out from University of Copenhagen – Anti-biofilm Developer
Early stage development of c-di-GMP technology against E.coli.